H epatitis C virus (HCV) infection contributes significantly to human morbidity and mortality worldwide, and new and better therapeutics are urgently needed. 1 However, the evaluation of candidate antiviral compounds is hindered by the absence of readily available animal models. Chimpanzees (Pan troglodytes) are susceptible to HCV infection, but are endangered as a species and increasingly difficult to access for experimental studies. More recently developed murine models with chimeric human livers are technically challenging and, moreover, do not recapitulate pathogenesis because of underlying immunodeficiency. 2,3 GB virus B (GBV-B), a hepatotropic member of the Flaviviridae family with close phylogenetic relatedness to HCV (genus Hepacivirus), 4,5 thus provides a potentially useful surrogate for animal studies of hepatitis C. It is capable of infecting and causing hepatitis in several different nonendangered species of New World primates 6-9 and, like HCV, can establish a persistent infection associated with chronic liver disease. 10 The GBV-B and HCV genomes share many similarities and